Letter: C-reactive protein: An Important Inflammatory Marker of Coronary Atherosclerotic Disease or an Innocent Bystander?

Abstract

Get full access to this article

View all access options for this article.

References

Zhao

Gao

Chen

Liu

C-reactive protein: an important inflammatory marker of coronary atherosclerotic disease. Angiology. 2026;77:145-160.

Paraskevas

Mikhailidis

DP.

C-reactive protein (CRP): more than just an innocent bystander?

Curr Med Res Opin. 2008;24: 75-8.

Casas

Shah

Cooper

, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol. 2006;35:922-31.

Pepys

MB.

CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol. 2005;25:1091-4.

Giannakopoulou

Antonopoulos

Panagiotakos

Serum inflammatory markers used in cardiovascular disease risk prediction models: a systematic review. Angiology. 2026;77:137-144.

Ridker

Everett

Thuren

, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31.

Weber

von Hundelshausen

CANTOS trial validates the inflammatory pathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting. Circ Res. 2017;121:1119-21.

Arnett

Blumenthal

Albert

, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596-646.

Visseren

FLJ

Mach

Smulders

, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337.

10.

Vrints

Andreotti

Koskinas

, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415-537.